Christian Reich, MD, PhD
VP RWE Systems
Christian has more than 15 years of experience in life science research and medicine. He was a practicing physician in Berlin and Ulm, Germany before moving to the European Bioinformatics Institute to work on the Human Genome Project. He then joined the biotech industry in 1998, where he worked in various positions on typical challenges in drug research and development, such as gene sequence and expression analysis, clinical trial design and analysis, systems biology, and outcome research, applying computational methods to large scale biological data. Christian is vice president of Real-World Evidence Systems at IMS Health. He received his bachelor’s degree in preclinical training from Humboldt University in Berlin and holds his M.D. and doctorate from the Medical University of Lübeck, Germany where he focused his research on T-cell activation and regulation.
Reich served as a principal investigator of the Observational Medical Outcomes Partnership (OMOP), a public-private partnership chaired by the Food and Drug Administration, where he was responsible for the design and construction of the OMOP Vocabulary.
Boyce RD, Ryan PB, Noren GN, et al. Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest. Drug Saf. 2014 Jul 2;2:2.
Stang P, Ryan P, Hartzema AG, et al. Development and Evaluation of Infrastructure and Analytic Methods for Systematic Drug Safety Surveillance: Lessons and Resources from the Observational Medical Outcomes Partnership. In: Elizabeth B. Andrews NM, editor. Mann’s Pharmacovigilance. Third ed: Wiley-Blackwell; 2014. p. 866.
Reich CG, Ryan PB, Suchard MA. The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system. Drug Saf. 2013 Oct;36(Suppl 1):S195-204. doi: 10.1007/s40264-013-0112-0.
Reich CG, Ryan PB, Schuemie MJ. Alternative outcome definitions and their effect on the performance of methods for observational outcome studies. Drug Saf. 2013 Oct;36(Suppl 1):S181-93. doi: 10.1007/s40264-013-0111-1.
Ryan PB, Stang PE, Overhage JM, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013 Oct;36(Suppl 1):S143-58. doi: 10.1007/s40264-013-0108-9.
Hartzema AG, Reich CG, Ryan PB, et al. Managing data quality for a drug safety surveillance system. Drug Saf. 2013 Oct;36(Suppl 1):S49-58. doi: 10.1007/s40264-013-0098-7.
Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012 Aug;45(4):689-96. doi: 10.1016/j.jbi.2012.05.002. Epub Jun 7.
Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60. doi: 10.1136/amiajnl-2011-000376. Epub 2011 Oct 28.
Stang PE, Ryan PB, Dusetzina SB, et al. Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature. Health Outcomes Research in Medicine. 2012 2//;3(1):e37-e44.
Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010 Nov 2;153(9):600-6. doi: 10.7326/0003-4819-153-9-201011020-00010.